Floatz logo

435 assets in Melanoma

Therapeutic assets addressing Melanoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
1-PIPERIDINEETHANOL, .ALPHA.-((2-NITRO-1H-IMIDAZOL-1-YL)METHYL)-, HYDROCHLORIDE (1:1), (.ALPHA.R)-
Melanoma
Yana NajjarP2CCC (48)
Adavosertib
Melanoma
National Cancer Institute (NCI)P2CCC (48)
Aguix
Melanoma
Brigham and Women's HospitalP2CCC (48)
Apg 115
Melanoma
Ascentage Pharma Group Inc.P1/2CCC (48)
Azacytidine
Melanoma
National Cancer Institute (NCI)P1/2CCC (48)
Balstilimab
Melanoma
Targovax OyP2CCC (48)
bi-1607
Melanoma
BioInvent International ABP1/2CCC (48)
Bms 986253
Melanoma
Yana NajjarP1/2CCC (48)
Cdx 1140
Melanoma
University of Southern CaliforniaP1/2CCC (48)
Ceralasertib
Melanoma
AstraZenecaP2CCC (48)
Crizotinib
Melanoma
Charite University, Berlin, GermanyP2CCC (48)
Defactinib
Melanoma
National Cancer Institute (NCI)P2CCC (48)
doc1021
Melanoma
Diakonos Oncology CorporationP1/2CCC (48)
Domvanalimab
Melanoma
Diwakar DavarP2CCC (48)
Eb-Dtkn-401 Allogeneic Dual-Target Cspg4/Gd2 Car-Nk Cells
Melanoma
Beijing BiotechP1/2CCC (48)
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)
Melanoma
Grupo Español Multidisciplinar de MelanomaP2CCC (48)
Ensartinib
Melanoma
Memorial Sloan Kettering Cancer CenterP2CCC (48)
Etimupepimut
Melanoma
Memorial Sloan Kettering Cancer CenterP2CCC (48)
Famitinib
Melanoma
Shanghai Zhongshan HospitalP2CCC (48)
Fexagratinib
Melanoma
National Cancer Institute (NCI)P2CCC (48)
Gim-531
Melanoma
Georgiamune IncP1/2CCC (48)
Gsk-2636771
Melanoma
National Cancer Institute (NCI)P2CCC (48)
her3-dxd
Melanoma
Daiichi SankyoP2CCC (48)
ibi363
Melanoma
Innovent Biologics (Suzhou) Co. Ltd.P2CCC (48)
Iov-3001
Melanoma
Iovance Biotherapeutics, Inc.P1/2CCC (48)
Ipatasertib
Melanoma
National Cancer Institute (NCI)P2CCC (48)
Iron Dextran
Melanoma
Indiana UniversityP2CCC (48)
Larotrectinib
Melanoma
National Cancer Institute (NCI)P2CCC (48)
lnd101
Melanoma
Canadian Cancer Trials GroupP2CCC (48)
Osimertinib
Melanoma
National Cancer Institute (NCI)P2CCC (48)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493
Melanoma
National Cancer Institute (NCI)P2CCC (48)
Pd-L1 T-Hank
Melanoma
ImmunityBio, Inc.P2CCC (48)
Penpulimab
Melanoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.P2CCC (48)
Pertuzumab
Melanoma
National Cancer Institute (NCI)P2CCC (48)
Pudexacianinium Chloride
Melanoma
Astellas Pharma IncP2CCC (48)
qlf31907
Melanoma
Qilu Pharmaceutical Co., Ltd.P2CCC (48)
Rain-32
Melanoma
Rain Oncology IncP2CCC (48)
Retlirafusp Alfa
Melanoma
Shanghai Zhongshan HospitalP2CCC (48)
Rintatolimod
Melanoma
Roswell Park Cancer InstituteP2CCC (48)
Rosiglitazone
Melanoma
Dan ZandbergP2CCC (48)
Sapanisertib
Melanoma
National Cancer Institute (NCI)P2CCC (48)
Sarilumab
Melanoma
NYU Langone HealthP2CCC (48)
tqb2916
Melanoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.P2CCC (48)
Transcon Tlr7/8 Agonist
Melanoma
Ascendis Pharma Oncology Division A/SP1/2CCC (48)
Vismodegib
Melanoma
National Cancer Institute (NCI)P2CCC (48)
Zirconium Zr 89 Crefmirlimab Berdoxam
Melanoma
ImaginAb, Inc.P2CCC (48)
[212pb]vmt01
Melanoma
Perspective TherapeuticsP1/2CC (47)
Duvelisib
Melanoma
John KirkwoodP1/2CC (47)
Hbi 0201-Eso Tcrt
Melanoma
Hadassah Medical OrganizationP1/2CC (47)
Iov-4001
Melanoma
Iovance Biotherapeutics, Inc.P1/2CC (47)
Showing 151 to 200 of 435 assets
PreviousPage 4 of 9Next